Cardiology:每天饮用能量饮料超过2杯,会增加心血管疾病风险

2016-02-04 QQduhp 译 MedSci原创

CDC的数据显示,约31%12-17岁青少年经常饮用能量饮料,34%18-24岁青年人定期饮用添加有兴奋剂的能量饮料。 阿德莱德大学的药理学博士Ian Musgrave指出,在过去的十年里能量饮料普遍受到民众欢迎,民众希望借此减轻疲劳,减少困意并提高注意力。他和同事将研究成果发表在在Cardiology。 虽然含有咖啡因的能量饮料较多,但其中也可含有植物性兴奋剂、单糖和其他添加剂等。 为了深入调查

CDC的数据显示,约31%的12-17岁青少年经常饮用能量饮料,34%的18-24岁青年人定期饮用添加有兴奋物质的能量饮料。 


阿德莱德大学的药理学博士Ian Musgrave指出,在过去的十年里能量饮料普遍受到民众欢迎,民众希望借此减轻疲劳,减少困意并提高注意力。他和同事将研究成果发表在在Cardiology。 

虽然含有咖啡因的能量饮料较多,但其中也可含有植物性兴奋物质、单糖和其他添加剂等。 

为了深入调查和观察能量饮料对民众的影响,研究人员对2014-2015年间因心悸问题就诊于南澳大利亚医院急诊科的患者进行了探究。

研究人员指出,就诊急诊的患者中约70%的患者曾饮用过某种类型的能量饮料。 

研究人员发现一个更直接的联系:在受访患者中,36%的就诊患者在饮用能量饮料后24小时内去急诊就诊。这些患者中,有8位患者饮用能量饮料超过5种,1人饮用12种能量饮料,同时还饮酒。此外,他们发现,相比饮用能量饮料少于1杯/天的民众,饮用能量饮料更多的民众发生心悸的风险及频率更高。研究人员还指出,对于健康且无心脏病高危风险因素的民众而言,饮用能量饮料后可出现心率加快、心悸、胸痛等症状。  

Musgrave博士认为,学者们越来越担心含咖啡因的酒精饮料(CABs)对机体有害。2010年11月,FDA就曾强制要求7种CABs饮料退出销售市场。

Musgrave博士补充道:“含有酒精的饮料对人们的危害在于,它不仅削弱人们的思考和决断能力,同时也减慢能量饮料中咖啡因的分解代谢速度。”

他认为,尽管咖啡因是最安全的兴奋剂之一,但摄入含咖啡因的饮料会增加民众患心脏病的风险。这项研究有助于遏制民众无节制饮用能量饮料,推荐摄入量的最大剂量为2杯/天。

原始出处:

Scott Willoughby et al.A survey of energy drink consumption among young patients presenting to the emergency department with the symptom of palpitations,International Journal of Cardiology, 1 Feb,2016

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2069270, encodeId=522c20692e074, content=<a href='/topic/show?id=125e40988d' target=_blank style='color:#2F92EE;'>#Cardiology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4098, encryptionId=125e40988d, topicName=Cardiology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=316c73, createdName=caoliehu, createdTime=Thu Jan 19 15:42:00 CST 2017, time=2017-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781697, encodeId=66831e8169700, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Feb 25 22:42:00 CST 2016, time=2016-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73677, encodeId=2469e3677ef, content=学习了,谢谢。, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73801651090, createdName=1ddc978cm67(暂无匿称), createdTime=Fri Mar 25 06:00:00 CST 2016, time=2016-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1472983, encodeId=caff14e29836a, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Sat Feb 06 11:42:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497958, encodeId=d4bd149e958b9, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Sat Feb 06 11:42:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628738, encodeId=4e9e1628e3828, content=<a href='/topic/show?id=718f8429e5e' target=_blank style='color:#2F92EE;'>#能量饮料#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84297, encryptionId=718f8429e5e, topicName=能量饮料)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3df221187157, createdName=zhixianchen, createdTime=Sat Feb 06 11:42:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63344, encodeId=532d6334477, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a6b1686125, createdName=1de47ca2m12(暂无匿称), createdTime=Fri Feb 05 11:44:00 CST 2016, time=2016-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63319, encodeId=9b256331949, content=个性化, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Fri Feb 05 09:14:00 CST 2016, time=2016-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63291, encodeId=74ba63291d9, content=应该是。做的好,定量化, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Fri Feb 05 00:12:00 CST 2016, time=2016-02-05, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2069270, encodeId=522c20692e074, content=<a href='/topic/show?id=125e40988d' target=_blank style='color:#2F92EE;'>#Cardiology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4098, encryptionId=125e40988d, topicName=Cardiology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=316c73, createdName=caoliehu, createdTime=Thu Jan 19 15:42:00 CST 2017, time=2017-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781697, encodeId=66831e8169700, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Feb 25 22:42:00 CST 2016, time=2016-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73677, encodeId=2469e3677ef, content=学习了,谢谢。, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73801651090, createdName=1ddc978cm67(暂无匿称), createdTime=Fri Mar 25 06:00:00 CST 2016, time=2016-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1472983, encodeId=caff14e29836a, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Sat Feb 06 11:42:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497958, encodeId=d4bd149e958b9, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Sat Feb 06 11:42:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628738, encodeId=4e9e1628e3828, content=<a href='/topic/show?id=718f8429e5e' target=_blank style='color:#2F92EE;'>#能量饮料#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84297, encryptionId=718f8429e5e, topicName=能量饮料)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3df221187157, createdName=zhixianchen, createdTime=Sat Feb 06 11:42:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63344, encodeId=532d6334477, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a6b1686125, createdName=1de47ca2m12(暂无匿称), createdTime=Fri Feb 05 11:44:00 CST 2016, time=2016-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63319, encodeId=9b256331949, content=个性化, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Fri Feb 05 09:14:00 CST 2016, time=2016-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63291, encodeId=74ba63291d9, content=应该是。做的好,定量化, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Fri Feb 05 00:12:00 CST 2016, time=2016-02-05, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2069270, encodeId=522c20692e074, content=<a href='/topic/show?id=125e40988d' target=_blank style='color:#2F92EE;'>#Cardiology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4098, encryptionId=125e40988d, topicName=Cardiology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=316c73, createdName=caoliehu, createdTime=Thu Jan 19 15:42:00 CST 2017, time=2017-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781697, encodeId=66831e8169700, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Feb 25 22:42:00 CST 2016, time=2016-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73677, encodeId=2469e3677ef, content=学习了,谢谢。, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73801651090, createdName=1ddc978cm67(暂无匿称), createdTime=Fri Mar 25 06:00:00 CST 2016, time=2016-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1472983, encodeId=caff14e29836a, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Sat Feb 06 11:42:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497958, encodeId=d4bd149e958b9, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Sat Feb 06 11:42:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628738, encodeId=4e9e1628e3828, content=<a href='/topic/show?id=718f8429e5e' target=_blank style='color:#2F92EE;'>#能量饮料#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84297, encryptionId=718f8429e5e, topicName=能量饮料)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3df221187157, createdName=zhixianchen, createdTime=Sat Feb 06 11:42:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63344, encodeId=532d6334477, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a6b1686125, createdName=1de47ca2m12(暂无匿称), createdTime=Fri Feb 05 11:44:00 CST 2016, time=2016-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63319, encodeId=9b256331949, content=个性化, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Fri Feb 05 09:14:00 CST 2016, time=2016-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63291, encodeId=74ba63291d9, content=应该是。做的好,定量化, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Fri Feb 05 00:12:00 CST 2016, time=2016-02-05, status=1, ipAttribution=)]
    2016-03-25 1ddc978cm67(暂无匿称)

    学习了,谢谢。

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2069270, encodeId=522c20692e074, content=<a href='/topic/show?id=125e40988d' target=_blank style='color:#2F92EE;'>#Cardiology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4098, encryptionId=125e40988d, topicName=Cardiology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=316c73, createdName=caoliehu, createdTime=Thu Jan 19 15:42:00 CST 2017, time=2017-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781697, encodeId=66831e8169700, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Feb 25 22:42:00 CST 2016, time=2016-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73677, encodeId=2469e3677ef, content=学习了,谢谢。, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73801651090, createdName=1ddc978cm67(暂无匿称), createdTime=Fri Mar 25 06:00:00 CST 2016, time=2016-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1472983, encodeId=caff14e29836a, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Sat Feb 06 11:42:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497958, encodeId=d4bd149e958b9, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Sat Feb 06 11:42:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628738, encodeId=4e9e1628e3828, content=<a href='/topic/show?id=718f8429e5e' target=_blank style='color:#2F92EE;'>#能量饮料#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84297, encryptionId=718f8429e5e, topicName=能量饮料)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3df221187157, createdName=zhixianchen, createdTime=Sat Feb 06 11:42:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63344, encodeId=532d6334477, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a6b1686125, createdName=1de47ca2m12(暂无匿称), createdTime=Fri Feb 05 11:44:00 CST 2016, time=2016-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63319, encodeId=9b256331949, content=个性化, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Fri Feb 05 09:14:00 CST 2016, time=2016-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63291, encodeId=74ba63291d9, content=应该是。做的好,定量化, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Fri Feb 05 00:12:00 CST 2016, time=2016-02-05, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2069270, encodeId=522c20692e074, content=<a href='/topic/show?id=125e40988d' target=_blank style='color:#2F92EE;'>#Cardiology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4098, encryptionId=125e40988d, topicName=Cardiology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=316c73, createdName=caoliehu, createdTime=Thu Jan 19 15:42:00 CST 2017, time=2017-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781697, encodeId=66831e8169700, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Feb 25 22:42:00 CST 2016, time=2016-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73677, encodeId=2469e3677ef, content=学习了,谢谢。, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73801651090, createdName=1ddc978cm67(暂无匿称), createdTime=Fri Mar 25 06:00:00 CST 2016, time=2016-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1472983, encodeId=caff14e29836a, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Sat Feb 06 11:42:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497958, encodeId=d4bd149e958b9, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Sat Feb 06 11:42:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628738, encodeId=4e9e1628e3828, content=<a href='/topic/show?id=718f8429e5e' target=_blank style='color:#2F92EE;'>#能量饮料#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84297, encryptionId=718f8429e5e, topicName=能量饮料)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3df221187157, createdName=zhixianchen, createdTime=Sat Feb 06 11:42:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63344, encodeId=532d6334477, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a6b1686125, createdName=1de47ca2m12(暂无匿称), createdTime=Fri Feb 05 11:44:00 CST 2016, time=2016-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63319, encodeId=9b256331949, content=个性化, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Fri Feb 05 09:14:00 CST 2016, time=2016-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63291, encodeId=74ba63291d9, content=应该是。做的好,定量化, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Fri Feb 05 00:12:00 CST 2016, time=2016-02-05, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2069270, encodeId=522c20692e074, content=<a href='/topic/show?id=125e40988d' target=_blank style='color:#2F92EE;'>#Cardiology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4098, encryptionId=125e40988d, topicName=Cardiology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=316c73, createdName=caoliehu, createdTime=Thu Jan 19 15:42:00 CST 2017, time=2017-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781697, encodeId=66831e8169700, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Feb 25 22:42:00 CST 2016, time=2016-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73677, encodeId=2469e3677ef, content=学习了,谢谢。, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73801651090, createdName=1ddc978cm67(暂无匿称), createdTime=Fri Mar 25 06:00:00 CST 2016, time=2016-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1472983, encodeId=caff14e29836a, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Sat Feb 06 11:42:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497958, encodeId=d4bd149e958b9, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Sat Feb 06 11:42:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628738, encodeId=4e9e1628e3828, content=<a href='/topic/show?id=718f8429e5e' target=_blank style='color:#2F92EE;'>#能量饮料#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84297, encryptionId=718f8429e5e, topicName=能量饮料)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3df221187157, createdName=zhixianchen, createdTime=Sat Feb 06 11:42:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63344, encodeId=532d6334477, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a6b1686125, createdName=1de47ca2m12(暂无匿称), createdTime=Fri Feb 05 11:44:00 CST 2016, time=2016-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63319, encodeId=9b256331949, content=个性化, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Fri Feb 05 09:14:00 CST 2016, time=2016-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63291, encodeId=74ba63291d9, content=应该是。做的好,定量化, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Fri Feb 05 00:12:00 CST 2016, time=2016-02-05, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2069270, encodeId=522c20692e074, content=<a href='/topic/show?id=125e40988d' target=_blank style='color:#2F92EE;'>#Cardiology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4098, encryptionId=125e40988d, topicName=Cardiology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=316c73, createdName=caoliehu, createdTime=Thu Jan 19 15:42:00 CST 2017, time=2017-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781697, encodeId=66831e8169700, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Feb 25 22:42:00 CST 2016, time=2016-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73677, encodeId=2469e3677ef, content=学习了,谢谢。, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73801651090, createdName=1ddc978cm67(暂无匿称), createdTime=Fri Mar 25 06:00:00 CST 2016, time=2016-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1472983, encodeId=caff14e29836a, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Sat Feb 06 11:42:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497958, encodeId=d4bd149e958b9, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Sat Feb 06 11:42:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628738, encodeId=4e9e1628e3828, content=<a href='/topic/show?id=718f8429e5e' target=_blank style='color:#2F92EE;'>#能量饮料#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84297, encryptionId=718f8429e5e, topicName=能量饮料)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3df221187157, createdName=zhixianchen, createdTime=Sat Feb 06 11:42:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63344, encodeId=532d6334477, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a6b1686125, createdName=1de47ca2m12(暂无匿称), createdTime=Fri Feb 05 11:44:00 CST 2016, time=2016-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63319, encodeId=9b256331949, content=个性化, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Fri Feb 05 09:14:00 CST 2016, time=2016-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63291, encodeId=74ba63291d9, content=应该是。做的好,定量化, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Fri Feb 05 00:12:00 CST 2016, time=2016-02-05, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=2069270, encodeId=522c20692e074, content=<a href='/topic/show?id=125e40988d' target=_blank style='color:#2F92EE;'>#Cardiology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4098, encryptionId=125e40988d, topicName=Cardiology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=316c73, createdName=caoliehu, createdTime=Thu Jan 19 15:42:00 CST 2017, time=2017-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781697, encodeId=66831e8169700, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Feb 25 22:42:00 CST 2016, time=2016-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73677, encodeId=2469e3677ef, content=学习了,谢谢。, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73801651090, createdName=1ddc978cm67(暂无匿称), createdTime=Fri Mar 25 06:00:00 CST 2016, time=2016-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1472983, encodeId=caff14e29836a, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Sat Feb 06 11:42:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497958, encodeId=d4bd149e958b9, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Sat Feb 06 11:42:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628738, encodeId=4e9e1628e3828, content=<a href='/topic/show?id=718f8429e5e' target=_blank style='color:#2F92EE;'>#能量饮料#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84297, encryptionId=718f8429e5e, topicName=能量饮料)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3df221187157, createdName=zhixianchen, createdTime=Sat Feb 06 11:42:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63344, encodeId=532d6334477, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a6b1686125, createdName=1de47ca2m12(暂无匿称), createdTime=Fri Feb 05 11:44:00 CST 2016, time=2016-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63319, encodeId=9b256331949, content=个性化, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Fri Feb 05 09:14:00 CST 2016, time=2016-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63291, encodeId=74ba63291d9, content=应该是。做的好,定量化, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Fri Feb 05 00:12:00 CST 2016, time=2016-02-05, status=1, ipAttribution=)]
    2016-02-05 老段

    个性化

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=2069270, encodeId=522c20692e074, content=<a href='/topic/show?id=125e40988d' target=_blank style='color:#2F92EE;'>#Cardiology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4098, encryptionId=125e40988d, topicName=Cardiology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=316c73, createdName=caoliehu, createdTime=Thu Jan 19 15:42:00 CST 2017, time=2017-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781697, encodeId=66831e8169700, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Feb 25 22:42:00 CST 2016, time=2016-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73677, encodeId=2469e3677ef, content=学习了,谢谢。, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73801651090, createdName=1ddc978cm67(暂无匿称), createdTime=Fri Mar 25 06:00:00 CST 2016, time=2016-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1472983, encodeId=caff14e29836a, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Sat Feb 06 11:42:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497958, encodeId=d4bd149e958b9, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Sat Feb 06 11:42:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628738, encodeId=4e9e1628e3828, content=<a href='/topic/show?id=718f8429e5e' target=_blank style='color:#2F92EE;'>#能量饮料#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84297, encryptionId=718f8429e5e, topicName=能量饮料)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3df221187157, createdName=zhixianchen, createdTime=Sat Feb 06 11:42:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63344, encodeId=532d6334477, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a6b1686125, createdName=1de47ca2m12(暂无匿称), createdTime=Fri Feb 05 11:44:00 CST 2016, time=2016-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63319, encodeId=9b256331949, content=个性化, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Fri Feb 05 09:14:00 CST 2016, time=2016-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63291, encodeId=74ba63291d9, content=应该是。做的好,定量化, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Fri Feb 05 00:12:00 CST 2016, time=2016-02-05, status=1, ipAttribution=)]
    2016-02-05 dhzzm

    应该是。做的好,定量化

    0

相关威廉亚洲官网

BMJ Open:他汀对血脂异常发生率似乎没什么卵用

血脂异常是心血管疾病主要危险因素,而心血管疾病又是全球范围内主要死亡原因。研究者进行了一项横断面研究,探究初级医疗保健机构加拿大人群中血脂异常发生情况。该研究共纳入了134074名>20岁非妊娠成年人,通过加拿大威廉亚洲博彩公司 识别血脂异常,使用多因素回顾分析比较血脂异常情况。研究数据显示,纳入人群平均年龄59.2岁,其中55.8%是女性。34.8%的参与者没有血脂异常,有1种、2种、3种血脂异常的参与者分别

Gastroenterology:感染HCV对心血管疾病风险的影响

先前关于HCV和心血管风险的研究结果具有争议,因此研究者检索了PubMed Central、Medline、Embase等数据库上比较HCV患者和非HCV患者心血管发生率,或心血管疾病患者HCV发生率相关文献,进行荟萃分析HCV感染对心血管疾病相关发病率和死亡率的影响。最终纳入了22项研究,由3名研究人员独立提取数据,使用随机效应模型进行荟萃分析。研究结果显示,与非HCV感染的患者相比,感染HCV

2015年度心血管领域热点盘点

2015年,心血管领域涌现出了不少有重要意义的临床研究。近日,PracticeUpdate网站邀请心血管领域的知名学者选出其认为的年度热点研究。Dr. Joerg Herrmann:PURE研究之握力的预测价值作为一位医生,即使身处当今的数字化时代,也有一些研究结果出乎意外之外。在医生看见一位患者时,会对其身体情况有一个直接的感受。今年公布的PURE研究提示,握一握患者的手将提供更多的信息。当

Diabetes Obes Metab:短期补充维生素D能否影响HbA1c?

先前有研究表明25(OH)D含量与2型糖尿病和冠状动脉存在风险呈负相关,但并没有估计两者间的因果联系。研究者对糖尿病风险增加的人群进行了一项研究,探究短期内服用维生素D补充剂对心血管代谢疾病的预后影响。该双盲安慰剂对照随机试验共纳入了340名2型糖尿病风险增加成年人(非糖尿病的高血糖症或糖尿病风险评分阳性),将其随机分为维生素D2 100,000 IU或维生素D3 100,000 IU和安慰剂组。

Neurology:特发性正常压力脑积水(iNPH)的心血管因素

研究人员就血管危险因素和白质病变(WMLs)研究了疑似特发性正常压力脑积水(iNPH)的临床和影像学检查结果,使用了有代表性的人群为基础的样本进行巢式病例对照研究。从人群为基础的样本中,研究人员在1986年至2000年间对1235名年龄在70岁以上的参与者进行了CT和大脑的检查。研究人员确定了55人脑积水脑室扩大,也就是说,影像学结果与iNPH是一致的。其中,26人的临床症状是符合疑似iNPH国际

Ann Rheum Dis:秋水仙素或可降低心血管事件风险

秋水仙素可能对心血管患者有益,但关于痛风患者的心血管事件研究数据稀少,本研究旨在评估痛风患者使用秋水仙素后的心血管事件发生率及全因死亡率。 研究人员分析了来自2006-2011年电子病例(EMR)数据库以及医疗索赔数据库的501名新用秋水仙素的痛风患者,并随访约16.5个月。使用秋水仙素组中有28名发生心血管事件,对照组中82名发生心血管事件,事件发生率分别为35.6/1000人年和81.8/1